Based on the Fulcrum Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Fulcrum Therapeutics Inc is USD 12.00 over the next 12 months. Fulcrum Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Fulcrum Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Fulcrum Therapeutics Inc’s stock price was USD 7.06. Fulcrum Therapeutics Inc’s stock price has changed by -9.60% over the past week, -30.24% over the past month and +182.40% over the last year.
No recent analyst target price found for Fulcrum Therapeutics Inc
No recent average analyst rating found for Fulcrum Therapeutics Inc
Company Overview Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read Less
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a smal...Read More
Frequently Asked Questions About Fulcrum Therapeutics Inc (FULC) Stock
Based on ratings from 3 analysts Fulcrum Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on FULC's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for FULC is USD 12.00 over the next 12 months. The maximum analyst target price is USD 16 while the minimum anlayst target price is USD 6.
FULC stock's Price/Earning ratio is 267.00.
Our analysis grades FULC stock's Price / Earning ratio at F. This means that FULC stock's Price/Earning ratio is above 94% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this FULC may be a overvalued for its sector.
The last closing price of FULC's stock was USD 7.06.
The most recent market capitalization for FULC is USD 0.60B.
Based on targets from 3 analysts, the average taret price for FULC is projected at USD 12.00 over the next 12 months.
This means that FULC's stock price may go up by +69.97% over the next 12 months.
We can't find any ETFs which contains Fulcrum Therapeutics Inc's stock.
As per our most recent records Fulcrum Therapeutics Inc has 76 Employees.
Fulcrum Therapeutics Inc's registered address is 26 Landsdowne Street, Cambridge, MA, United States, 02139.
You can get more information about it from Fulcrum Therapeutics Inc's website at https://www.fulcrumtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for FULC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
